PL2266534T3 - Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia mukowiscydozy - Google Patents

Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia mukowiscydozy

Info

Publication number: PL2266534T3
Authority: PL; Poland
Prior art keywords: treatment; cystic fibrosis; tobramycin combination; fosfomycin; aerosolized
Prior art date: 2004-05-17

Application number

PL10168285T

Other languages

English (en)

Inventor

William Baker

David Macleod

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-17

Filing date

2005-05-02

Publication date

2013-02-28

2005-05-02 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2013-02-28 Publication of PL2266534T3 publication Critical patent/PL2266534T3/pl

Links

201000003883 Cystic fibrosis Diseases 0.000 title 1
YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 title 1
229960000308 fosfomycin Drugs 0.000 title 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 title 1
229960000707 tobramycin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Dispersion Chemistry (AREA)
Mechanical Engineering (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL10168285T 2004-05-17 2005-05-02 Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia mukowiscydozy PL2266534T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US57173904P	2004-05-17	2004-05-17
US65900505P	2005-03-03	2005-03-03
EP05772820A EP1750667B1 (en)	2004-05-17	2005-05-02	Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
EP10168285A EP2266534B1 (en)	2004-05-17	2005-05-02	Aerosolized Fosfomycin/Tobramycin combination for the treatment of Cystic Fibrosis

Publications (1)

Publication Number	Publication Date
PL2266534T3 true PL2266534T3 (pl)	2013-02-28

Family

ID=35394588

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL05772820T PL1750667T3 (pl)	2004-05-17	2005-05-02	Aerozolizowana kombinacja fosfomycyny/aminoglikozydu do leczenia bakteryjnych zakażeń oddechowych
PL10168285T PL2266534T3 (pl)	2004-05-17	2005-05-02	Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia mukowiscydozy
PL10182347T PL2316419T3 (pl)	2004-05-17	2005-05-02	Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia bakteryjnych infekcji dróg oddechowych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL05772820T PL1750667T3 (pl)	2004-05-17	2005-05-02	Aerozolizowana kombinacja fosfomycyny/aminoglikozydu do leczenia bakteryjnych zakażeń oddechowych

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL10182347T PL2316419T3 (pl)	2004-05-17	2005-05-02	Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia bakteryjnych infekcji dróg oddechowych

Country Status (18)

Country	Link
US (4)	US7943118B2 (pl)
EP (3)	EP2266534B1 (pl)
JP (1)	JP4745340B2 (pl)
AR (1)	AR048793A1 (pl)
AT (1)	ATE493969T1 (pl)
AU (2)	AU2005244153B2 (pl)
BR (1)	BRPI0509026A (pl)
CA (1)	CA2564546C (pl)
CY (3)	CY1112004T1 (pl)
DE (1)	DE602005025754D1 (pl)
DK (3)	DK1750667T3 (pl)
ES (3)	ES2392389T3 (pl)
IL (2)	IL179277A (pl)
PL (3)	PL1750667T3 (pl)
PT (3)	PT1750667E (pl)
SI (3)	SI2316419T1 (pl)
TW (1)	TWI409074B (pl)
WO (1)	WO2005110022A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2392389T3 (es)	2004-05-17	2012-12-10	Gilead Sciences, Inc.	Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
US20060210483A1 (en) *	2005-03-02	2006-09-21	Kodsi Robert E	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20100093650A1 (en) *	2006-10-11	2010-04-15	Laboratories Smb S.A.	Pharmaceutical Anit-Infective Composition for Inhalation
JP2010512350A (ja) *	2006-12-11	2010-04-22	ダラグレキュル・アンパルトセルスカブ	ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
EP2018864A1 (en)	2007-07-23	2009-01-28	Biomet Deutschland GmbH	Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
DE102008046610A1 (de) *	2008-09-09	2010-03-11	Biomet Deutschland Gmbh	Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
JP2012506435A (ja) *	2008-10-21	2012-03-15	ギリアードサイエンシーズ，インコーポレイテッド	眼の感染症、耳の感染症、および皮膚の感染症の処置および予防のためのホスホマイシン／トブラマイシンの組み合わせ
AU2010324997A1 (en)	2009-11-24	2012-05-31	Gilead Sciences, Inc.	Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
EP2515935A4 (en) *	2009-12-22	2013-08-28	Kalobios Pharmaceuticals Inc	METHOD FOR TREATING STAPHYLOCOCCUS INFECTION IN A PATIENT WITH PSEUDOMONAS AERUGINOSA INFECTION WITH LOW PATHOGEN LEVEL
US20130164351A1 (en) *	2010-08-30	2013-06-27	Cempra Pharmaceuticals Inc.	Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012154483A1 (en) *	2011-05-06	2012-11-15	Gilead Sciences, Inc.	Dry powder fosfomycin/tobramycin formulation for inhalation
US9572774B2 (en)	2011-05-19	2017-02-21	Savara Inc.	Dry powder vancomycin compositions and associated methods
US8826904B2 (en)	2011-07-12	2014-09-09	Cardeas Pharma Corporation	Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
US8603439B2 (en) *	2011-07-12	2013-12-10	Cardeas Pharma Inc.	Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
EP2567691B1 (en)	2011-09-12	2014-12-24	Meiji Seika Pharma Co., Ltd.	Aqueous compositions comprising arbekacin
MX2016002524A (es) *	2013-08-26	2016-10-26	Cardeas Pharma Corp	Formulaciones de aminoglucosidos y fosfomicina en una combinacion que tiene propiedades quimicas mejoradas.
EP3219305A1 (de) *	2016-03-16	2017-09-20	Apostolos Georgopoulos	Fosfomycin-formulierung zur parenteralen verabreichung
IT201900007007A1 (it) *	2019-05-20	2020-11-20	Liofilchem Srl	Kit e metodo per il test di suscettibilità alla fosfomicina con il metodo dell’agar diluizione.
US20230372492A1 (en) *	2020-10-01	2023-11-23	Mississippi State University	Drugs conjugated with hexose phosphate and methods of making and using same
WO2024086892A1 (en) *	2022-10-26	2024-05-02	The George Institute for Global Health	Stable api formulations comprising micronized tobramycin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5750919A (en)	1980-09-16	1982-03-25	Meiji Seika Kaisha Ltd	Agent for reducing side effect
JPS58134028A (ja)	1982-02-05	1983-08-10	Meiji Seika Kaisha Ltd	アミノ配糖体抗生物質腎毒性の軽減乃至予防剤
GB9103291D0 (en) *	1991-02-15	1991-04-03	Waverley Pharma Ltd	Transfer adaptor
US5488038A (en)	1992-11-27	1996-01-30	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai	Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5508269A (en)	1994-10-19	1996-04-16	Pathogenesis Corporation	Aminoglycoside formulation for aerosolization
JPH09183730A (ja)	1995-05-10	1997-07-15	Meiji Seika Kaisha Ltd	ホスホマイシン鏡像異性体を含んでなる医薬
US6083922A (en)	1996-04-02	2000-07-04	Pathogenesis, Corp.	Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6413946B1 (en)	1997-10-03	2002-07-02	Meiji Seika Kaisha, Ltd.	Composition for treatment of diabetes and treatment of diabetes
CN1348377A (zh)	1998-12-17	2002-05-08	希龙公司	用气溶胶化的抗生素治疗严重慢性支气管炎(支气管扩张症)的方法
US20020061281A1 (en) *	1999-07-06	2002-05-23	Osbakken Robert S.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ523693A (en)	2000-07-10	2004-08-27	Chiron Corp	Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2005511477A (ja)	2001-03-19	2005-04-28	プラエシスファーマシューティカルズインコーポレーテッド	持続放出のための医薬調合物
ES2261735T3 (es)	2001-05-18	2006-11-16	Chiron Corporation	Sistema para la administracion de una formulacion de tobramicina.
ES2222294T3 (es)	2001-07-02	2005-02-01	Chiesi Farmaceutici S.P.A.	Formulacion optimizada de tobramicina para administracion en forma de aerosol.
JP2005508220A (ja) *	2001-10-24	2005-03-31	パーリ・ゲーエムベーハー	薬用組成物調製用具
TW200403072A (en) *	2002-01-23	2004-03-01	Upjohn Co	Combination therapy for the treatment of bacterial infections
US7452524B2 (en)	2004-01-27	2008-11-18	Gilead Sciences, Inc.	Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
ES2392389T3 (es)	2004-05-17	2012-12-10	Gilead Sciences, Inc.	Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
US7838532B2 (en)	2005-05-18	2010-11-23	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
ES2798263T3 (es)	2005-12-08	2020-12-10	Insmed Inc	Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
JP2010512350A (ja)	2006-12-11	2010-04-22	ダラグレキュル・アンパルトセルスカブ	ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
WO2008106584A1 (en)	2007-02-28	2008-09-04	Paringenix, Inc.	O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
MX2011004375A (es)	2008-10-23	2013-03-07	Vertex Pharma	Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
US8314239B2 (en)	2008-10-23	2012-11-20	Vertex Pharmaceutical Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2010324997A1 (en)	2009-11-24	2012-05-31	Gilead Sciences, Inc.	Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease

2005
- 2005-05-02 ES ES10168285T patent/ES2392389T3/es not_active Expired - Lifetime
- 2005-05-02 ES ES05772820T patent/ES2358024T3/es not_active Expired - Lifetime
- 2005-05-02 DK DK05772820.6T patent/DK1750667T3/da active
- 2005-05-02 SI SI200531577T patent/SI2316419T1/sl unknown
- 2005-05-02 DE DE602005025754T patent/DE602005025754D1/de not_active Expired - Lifetime
- 2005-05-02 PL PL05772820T patent/PL1750667T3/pl unknown
- 2005-05-02 US US11/596,566 patent/US7943118B2/en not_active Expired - Fee Related
- 2005-05-02 AT AT05772820T patent/ATE493969T1/de active
- 2005-05-02 EP EP10168285A patent/EP2266534B1/en not_active Expired - Lifetime
- 2005-05-02 PT PT05772820T patent/PT1750667E/pt unknown
- 2005-05-02 DK DK10182347.4T patent/DK2316419T3/da active
- 2005-05-02 AU AU2005244153A patent/AU2005244153B2/en not_active Ceased
- 2005-05-02 BR BRPI0509026-1A patent/BRPI0509026A/pt active Search and Examination
- 2005-05-02 EP EP05772820A patent/EP1750667B1/en not_active Expired - Lifetime
- 2005-05-02 WO PCT/US2005/014690 patent/WO2005110022A2/en not_active Ceased
- 2005-05-02 PT PT10182347T patent/PT2316419E/pt unknown
- 2005-05-02 SI SI200531250T patent/SI1750667T1/sl unknown
- 2005-05-02 DK DK10168285.4T patent/DK2266534T3/da active
- 2005-05-02 SI SI200531600T patent/SI2266534T1/sl unknown
- 2005-05-02 EP EP10182347A patent/EP2316419B1/en not_active Expired - Lifetime
- 2005-05-02 PL PL10168285T patent/PL2266534T3/pl unknown
- 2005-05-02 PT PT10168285T patent/PT2266534E/pt unknown
- 2005-05-02 PL PL10182347T patent/PL2316419T3/pl unknown
- 2005-05-02 ES ES10182347T patent/ES2388420T3/es not_active Expired - Lifetime
- 2005-05-02 CA CA2564546A patent/CA2564546C/en not_active Expired - Fee Related
- 2005-05-02 JP JP2007527253A patent/JP4745340B2/ja not_active Expired - Fee Related
- 2005-05-16 AR ARP050101997A patent/AR048793A1/es not_active Application Discontinuation
- 2005-05-16 TW TW094115733A patent/TWI409074B/zh not_active IP Right Cessation
2006
- 2006-11-14 IL IL179277A patent/IL179277A/en active IP Right Grant
2009
- 2009-12-07 AU AU2009243536A patent/AU2009243536B2/en not_active Ceased
2010
- 2010-12-14 US US12/967,645 patent/US8361444B2/en not_active Expired - Fee Related
2011
- 2011-03-09 CY CY20111100268T patent/CY1112004T1/el unknown
- 2011-04-13 US US13/085,576 patent/US8409549B2/en not_active Expired - Fee Related
2012
- 2012-09-05 CY CY20121100798T patent/CY1113283T1/el unknown
- 2012-09-14 US US13/616,544 patent/US8980226B2/en not_active Expired - Fee Related
- 2012-11-09 CY CY20121101067T patent/CY1113319T1/el unknown
2013
- 2013-04-02 IL IL225529A patent/IL225529A/en active IP Right Grant

Also Published As

Publication number	Publication date
PT2266534E (pt)	2012-10-09
SI1750667T1 (sl)	2011-04-29
WO2005110022A2 (en)	2005-11-24
PL1750667T3 (pl)	2011-06-30
IL179277A0 (en)	2007-05-15
IL179277A (en)	2013-04-30
ES2392389T3 (es)	2012-12-10
PL2316419T3 (pl)	2012-12-31
US7943118B2 (en)	2011-05-17
CY1113319T1 (el)	2016-04-13
EP2266534B1 (en)	2012-09-26
CY1112004T1 (el)	2015-11-04
JP2007538075A (ja)	2007-12-27
DK2316419T3 (da)	2012-10-22
EP1750667A4 (en)	2007-07-11
JP4745340B2 (ja)	2011-08-10
US20110189103A1 (en)	2011-08-04
CY1113283T1 (el)	2016-04-13
DE602005025754D1 (de)	2011-02-17
WO2005110022A3 (en)	2006-04-06
PT2316419E (pt)	2012-10-22
EP2266534A1 (en)	2010-12-29
BRPI0509026A (pt)	2007-09-18
US20110117030A1 (en)	2011-05-19
CA2564546C (en)	2013-02-26
US8361444B2 (en)	2013-01-29
IL225529A (en)	2014-08-31
US20070218013A1 (en)	2007-09-20
AU2005244153A1 (en)	2005-11-24
SI2316419T1 (sl)	2012-10-30
EP2316419B1 (en)	2012-07-11
PT1750667E (pt)	2011-03-11
EP2316419A1 (en)	2011-05-04
HK1151191A1 (en)	2012-01-27
AU2005244153B2 (en)	2009-10-29
US20130071442A1 (en)	2013-03-21
AR048793A1 (es)	2006-05-24
SI2266534T1 (sl)	2012-12-31
EP1750667B1 (en)	2011-01-05
CA2564546A1 (en)	2005-11-24
US8409549B2 (en)	2013-04-02
IL225529A0 (en)	2013-06-27
ES2388420T3 (es)	2012-10-15
TWI409074B (zh)	2013-09-21
DK1750667T3 (da)	2011-04-26
AU2009243536A1 (en)	2009-12-24
ATE493969T1 (de)	2011-01-15
HK1157637A1 (en)	2012-07-06
DK2266534T3 (da)	2013-01-14
ES2358024T3 (es)	2011-05-04
EP1750667A2 (en)	2007-02-14
TW200608983A (en)	2006-03-16
US8980226B2 (en)	2015-03-17
AU2009243536B2 (en)	2012-03-22

Publication	Publication Date	Title
SI2266534T1 (sl)	2012-12-31	Aerosolizirana kombinacija fosfomicin/tobramicin za zdravljenje cistične fibroze
EG24526A (en)	2009-08-30	Atomizer for distributing liquids for medical purposes
ZA200902805B (en)	2010-07-28	Motion-sensing air freshener of the spray type
ZA200803440B (en)	2009-03-25	Compounds for the treatment of metabolic disorders
PL1931478T3 (pl)	2013-10-31	Dysza rozpylająca dla dwóch płynów
GB0420772D0 (en)	2004-10-20	Spraying gun
PT1530466E (pt)	2015-02-24	Utilização de nintedanib para o tratamento de fibrose pulmonar
EP1954356A4 (en)	2017-12-13	Spray nozzles
ZA200704391B (en)	2008-08-27	Treatment and control of severe infections including cystic fibrosis
IL189171A (en)	2015-10-29	Use of Fat-Glycosaminoglycan or Fat-Carboxymethyl Cellulose Couplings for the Treatment of Cystic Fibrosis Treatment
EP1908527B8 (en)	2013-06-19	Electrostatic atomizer
EP1972385A4 (en)	2010-06-16	DROPLET APPLICATOR
PL1945243T3 (pl)	2015-12-31	Zastosowanie kalcytoniny w leczeniu rzs
GB0602651D0 (en)	2006-03-22	Spray gun
GB2423035B (en)	2007-04-18	Spray gun
GB0514000D0 (en)	2005-08-17	Electrostatic atomiser
ZA200704977B (en)	2008-11-26	Nebulizer formulation
GB0425333D0 (en)	2004-12-22	Self-steering axle
GB0203808D0 (en)	2002-04-03	The treatment of cystic fibrosis
PL378089A1 (pl)	2007-05-28	Sposób mycia nebulizera mikrokapilarnego
AU2005900007A0 (en)	2005-01-20	Osteoporosis treatment having anti-hypocalcemia effect
AU2005904525A0 (en)	2005-09-01	Liver-directed Gene Therapy
AU2004903188A0 (en)	2004-07-01	Treatment of myocardial fibrosis
PL376649A1 (pl)	2007-02-19	Wkładka do dyszy rozpylającej oraz dysza rozpylająca
IL162123A0 (en)	2005-11-20	Rotary sprinkler of the opposed nozzle type